Guardian Bio is a cancer therapeutics platform creating the next generation of cell therapies to tackle solid tumors. Our cell therapies are based on recently defined conventional dendritic cells (cDCs) and have a full toolkit to both activate and redirect a diverse range of immune cells against multiple tumor antigens. This makes them uniquely positioned to address the challenges associated with solid tumors. Our goal is to bring immunotherapy to a new world of patients.
The Guardian Bio platform has already shown in vitro the ability to selectively activate killer T cells against several cancer targets simultaneously - even from advanced cancer patient material. This results in effective killing of on-target cells with little off-target killing. Our first indications include subsets of head and neck, breast, and lung cancer, where we have physician support.
Guardian Bio’s founding team has expertise across immuno-oncology, cell therapy, and manufacturing, and includes one of the original pioneers of dendritic cell therapy. Our Advisors include the president of the AACR and head of the Duke Cancer Institute.
We are currently seeking a $3m Seed round to complete our preclinical work and prepare for our first clinical trials, planned for late 2024/early 2025.
The Guardian Bio platform has already shown in vitro the ability to selectively activate killer T cells against several cancer targets simultaneously - even from advanced cancer patient material. This results in effective killing of on-target cells with little off-target killing. Our first indications include subsets of head and neck, breast, and lung cancer, where we have physician support.
Guardian Bio’s founding team has expertise across immuno-oncology, cell therapy, and manufacturing, and includes one of the original pioneers of dendritic cell therapy. Our Advisors include the president of the AACR and head of the Duke Cancer Institute.
We are currently seeking a $3m Seed round to complete our preclinical work and prepare for our first clinical trials, planned for late 2024/early 2025.
Speaker
